Description

Wolverine Stack (BPC‑157 + TB‑500)

Description

• A combined investigational peptide regimen pairing BPC‑157 (Body Protection Compound‑157) and TB‑500 (Thymosin Beta‑4) intended for research into tissue repair, inflammation modulation, and recovery enhancement.
• Designed as a preclinical/translational research combination to study synergistic effects on healing, angiogenesis, and extracellular matrix remodeling.

Key benefits (research findings)

• BPC‑157: promotes angiogenesis, gut and soft‑tissue repair, modulation of inflammatory responses, and improved tendon/ligament healing in animal models.
• TB‑500: supports cell migration, actin cytoskeleton remodeling, decreased fibrosis, and accelerated wound closure in preclinical studies.
• Combined: may provide complementary mechanisms—BPC‑157 enhancing local angiogenesis and tissue protection while TB‑500 facilitates cell motility and matrix remodeling—potentially improving overall tissue regeneration in experimental systems.

Primary uses

• Preclinical and translational research into musculoskeletal repair, tendon/ligament injuries, wound healing, and inflammatory tissue disorders.
• Mechanistic studies examining angiogenesis, extracellular matrix dynamics, anti‑fibrotic effects, and combined peptide interactions.

Suggested use (research guidance)

• Use only per institutional protocols and supplier/PI‑validated dosing regimens; common research routes include local injection, systemic parenteral delivery, or topical formulations depending on study design.
• Establish dose–response and timing in pilot studies; consider separate and combined arms to evaluate synergy and safety.
• Maintain rigorous controls, blinding, and ethical approvals for animal or human translational research.

Safety and storage

• Both peptides are investigational; human safety, optimal dosing, and long‑term effects are not fully established. Avoid unsupervised human use.
• Potential adverse effects observed in studies include local injection reactions and transient systemic responses; comprehensive toxicity profiling required for clinical translation.
• Handle using appropriate laboratory PPE, sterile technique, and containment. Store lyophilized peptides per supplier instructions (typically refrigerated or frozen) and protect reconstituted solutions from repeated freeze–thaw and prolonged room‑temperature exposure.

Regulatory and ethical notes

• Status: investigational/preclinical in many jurisdictions. Use only with institutional review, ethical approval, and applicable regulatory compliance.
• Not a replacement for approved medical treatments—clinical use should occur only within authorized trials or under regulatory pathways.

Quick facts

• Mechanisms: BPC‑157 (gut/tissue protective, pro‑angiogenic, anti‑inflammatory), TB‑500 (actin modulation, pro‑migration, anti‑fibrotic).
• Intended audience: research institutions and regulated translational programs.
• Procurement and handling: obtain through legitimate scientific suppliers with institutional purchasing and approvals.

Research Use Only Disclaimer

Products sold by SoCo Peptides are intended strictly for laboratory research purposes only.

These compounds are not intended for human consumption, veterinary use, household use, cosmetic use, or therapeutic application. They are not drugs, foods, or dietary supplements and have not been evaluated or approved by the FDA.

By purchasing from this website, the customer represents that they are a qualified researcher or laboratory professional and understand the risks associated with handling research materials.

All products must be handled by trained professionals in appropriate research facilities and in accordance with all applicable laws and regulations.

SoCo Peptides makes no guarantees or claims regarding safety, effectiveness, or medical benefit.